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The PRogram In Support of Moms (PRISM):
study protocol for a cluster randomized
controlled trial of two active interventions
addressing perinatal depression in obstetric
settings
Tiffany A. Moore Simas1,2,3,4,5,7* , Linda Brenckle4, Padma Sankaran4, Grace A. Masters1, Sharina Person1,5,
Linda Weinreb6,9, Jean Y. Ko10,11, Cheryl L. Robbins10, Jeroan Allison1,5 and Nancy Byatt1,2,4,5,8
Abstract
Background: Perinatal depression, the most common pregnancy complication, is associated with negative
maternal-offspring outcomes. Despite existence of effective treatments, it is under-recognized and under-treated.
Professional organizations recommend universal screening, yet multi-level barriers exist to ensuring effective
diagnosis, treatment, and follow-up. Integrating mental health and obstetric care holds significant promise for
addressing perinatal depression. The overall study goal is to compare the effectiveness of two active interventions:
(1) the Massachusetts Child Psychiatry Access Program (MCPAP) for Moms, a state-wide, population-based program,
and (2) the PRogram In Support of Moms (PRISM) which includes MCPAP for Moms plus a proactive, multifaceted,
practice-level intervention with intensive implementation support.
Methods: This study is conducted in two phases: (1) a run-in phase which has been completed and involved
practice and patient participant recruitment to demonstrate feasibility for the second phase, and (2) a cluster
randomized controlled trial (RCT), which is ongoing, and will compare two active interventions 1:1 with ten Ob/Gyn
practices as the unit of randomization. In phase 1, rates of depressive symptoms and other demographic and
clinical features among patients were examined to inform practice randomization. Patient participants to be
recruited in phase 2 will be followed longitudinally until 13 months postpartum; they will have 3–5 total study visits
depending on whether their initial recruitment and interview was at 4–24 or 32–40 weeks gestation, or 1–3 months
postpartum. Sampling throughout pregnancy and postpartum will ensure participants with different depressive
symptom onset times. Differences in depression symptomatology and treatment participation will be compared
between patient participants by intervention arm.
(Continued on next page)
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Discussion: This manuscript describes the full two-phase study protocol. The study design is innovative because it
combines effectiveness with implementation research designs and integrates critical components of participatory
action research. Our approach assesses the feasibility, acceptance, efficacy, and sustainability of integrating a
stepped-care approach to perinatal depression care into ambulatory obstetric settings; an approach that is flexible
and can be tailored and adapted to fit unique workflows of real-world practices.
Trial registration: ClinicalTrials.gov Identifier: NCT02760004, registered prospectively on May 3, 2016.
Keywords: Pregnancy, Postpartum, Perinatal, Depression, Integrated care, Methods, Protocol, Intervention,
Implementation randomized controlled trial
Background
Perinatal depression (Major and Minor Depressive
Disorder occurring during pregnancy or within one year of
delivery), affecting upwards of one in seven women, is the
most common complication of pregnancy [1]. Despite be-
ing associated with negative maternal [2], birth [3], infant
[4] and child outcomes [5–7], which are mitigated by ef-
fective treatment [8] that includes psychopharmacology
and psychotherapy [9], perinatal depression remains
under-diagnosed [10–13] and under-treated [14]. Recog-
nizing the magnitude of this problem, professional soci-
eties, policy makers, and other stakeholders recommend
universal screening of pregnant and/or postpartum women
using validated tools [1, 15–18].
Screening for depression is widely accepted by perinatal
women and Ob/Gyn providers [19, 20]. However, screening
alone does not translate into treatment participation given
multi-level barriers to care. Provider and systems-level
barriers include: (a) lack of obstetric provider training in
technical aspects of depression care [20–22] and relevant
communication skills [23]; (b) absence of standardized
processes and procedures for integrateding obstetric and
depression care [23, 24]; (c) lack of mental health providers
willing to treat pregnant women [24]; (d) lack of referral
networks [23–27]; and, (e) inadequate capacity and re-
sources to ensure depression evaluation, treatment, follow-
up, and care coordination [23–29].
The obstetric practice setting holds significant promise as
a place to address depression in perinatal women, with ap-
proximately six million pregnancies occurring annually in
women age 15–44 years in the United States [30]. Obstetric
providers are often the only medical professionals that
young women see and thus their practices need supports to
adequately address depression in perinatal women [20].
Even in low risk pregnancies, women will have 12–15 visits
in under a year [31], thus providing ample opportunities to
screen in the context of obstetric care. In an effort to set
relevant standards, the Council on Patient Safety in
Women’s Health Care developed an evidence informed pa-
tient safety bundle [15]. The bundle provides broad
direction and is well-aligned with the American College of
Obstetricians and Gynecologists’ recommendations to
screen in the context of systems that ensure effective diag-
nosis, treatment, and follow-up [1, 15].
The care of women is lagging-behind changing care stan-
dards [1, 15] and will be further challenged to advance
without purposeful efforts aimed at innovating mental
health care delivery in obstetric settings. Translating inte-
grated, stepped-care models, as in models that provide spe-
cific treatment protocols in response to illness severity [32],
to obstetric settings could provide a solution. It is well-
established that these models effectively integrate depres-
sion treatment into primary care settings and improve the
quality of mental health care and depression outcomes
[33]. Such approaches have been introduced and evaluated
in outpatient obstetric practices with evidence supporting
feasibility, effectiveness, and acceptability [34]. However, it
remains an emerging field with current data focused mostly
on process measures [34] and with few studies assessing
symptom and outcome improvements for women and chil-
dren [35–39].
Our team developed and implemented a first-in na-
tion, state-wide, population-based program, the Massa-
chusetts Child Psychiatry Access Program for Moms
(MCPAP for Moms), designed to enhance the capacity
of obstetric providers to address perinatal depression
[40–42]. In so doing, we discovered opportunities to ad-
dress additional gaps in care. To achieve full remission
of depression symptoms, women with perinatal depres-
sion must: 1) be recognized via screening; 2) be assessed;
3) initiate treatment; 4) receive adequate treatment; and,
5) respond to treatment [43, 44]. MCPAP for Moms pro-
vides access to resources, however it does not include
the more intensive implementation and follow-up com-
ponents that Ob/Gyn practices and their patients need
[45]. Thus, building on MCPAP for Moms and inte-
grated care models, we have designed and piloted [46] a
more comprehensive practice-level intervention, the
PRogram In Support of Moms (PRISM) [35].
The aim of this paper is to describe the methods of a
large-scale, multi-site cluster-randomized controlled trial
(RCT) study protocol comparing two active interven-
tions in addressing perinatal depression in obstetric set-
tings. The first intervention is a population-based health
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program recognized as enhanced usual care (MCPAP for
Moms) that provides all Massachusetts obstetric practices
with access to telephonic psychiatric consultation and
mental health resources through care coordination services
[40, 42]. The second intervention is our practice-level
intervention (PRISM) [35, 47], a proactive, multifaceted,
and practical intervention that pairs MCPAP for Moms
with intensive implementation support and follow-up,
helping obstetric practices implement and sustain depres-
sion care, thus ensuring that women complete the entire
depression care pathway [44, 48].
Methods/design
Study Design & Overview
The first study phase (phase 1 or the run-in phase), which
has been completed, involved recruitment of practice and
patient participants as a run-in to demonstrate feasibility
for participation in the second phase of the RCT (see Add-
itional file 1 for study timeline). To inform randomization,
the prevalence of depressive symptomatology, clinical char-
acteristics, and treatment participation were examined
among phase 1 patient participants that received care in
the ten participating practices (see Additional file 2 for
study centers). The second phase (phase 2), which is on-
going and not yet completed, compares the two active in-
terventions in a 1:1 cluster RCT in which 10 Ob/Gyn
practices are randomized to MCPAP for Moms or PRISM
(MCPAP for Moms plus practice-level intervention). The
randomization approach was informed by our prior pilot
work [35, 47] and was done at the practice level because:
[1] practices are the natural intervention unit thus avoiding
“contamination” when exposed and unexposed physicians
are in the same office [49], and [2] patient-level
randomization is less feasible in this type of intervention
[49]. All patient participants are being recruited by the
study team outside of the practice environment to decrease
biases introduced by patient participants potentially receiv-
ing more attention or intervention in comparison to
patients in the same practice but not enrolled in the study.
Patient participants enter the designated study arm based
on where they receive care; they are blinded to whether
care is received at a practice randomized to MCPAP for
Moms or PRISM. Patient participants can be recruited at
any point during pregnancy through 3months postpartum
to ensure patient participants with differential depressive
symptom onset times. Patient participants to be recruited
in phase 2, depending on their recruitment and first inter-
view time point (4–24 weeks gestation, 32–40 weeks gesta-
tion, or 1–3months postpartum), will be followed 2–4
more times until 12months postpartum.
Overall this study aims to compare the effectiveness of
MCPAP for Moms alone versus PRISM in improving
depressive symptom severity (primary outcome) and
treatment participation in pregnancy through 12months
postpartum (secondary outcome). We hypothesize that
perinatal patient participants receiving care from practices
enrolled in PRISM will experience more improvement in
depression symptoms and increased treatment participa-
tion, than patient participants receiving care in practices
with MCPAP for Moms only. Secondarily, we will examine
provider and staff fidelity to PRISM, and estimate costs and
indicators of potential savings of PRISM.
The University of Massachusetts Medical School Insti-
tutional Review Board (UMass IRB) human subjects com-
mittee approved this study, providing review for the two
UMass Memorial Health Care-affiliated practices and one
practice without an IRB. In addition, six IRBs, affiliated
with the seven other participating practices, reviewed the
study. Of these, four ceded review to UMass IRB and two
retained independent review and approval. The CDC was
not engaged in conducting the research so its IRB
approval was not needed. The ClinialTrials.gov registry
number is NCT02760004. The study started in October
2015. As of July 2019, all practice recruitment, patient par-
ticipant recruitment for the run-in phase, and
randomization is complete. The phase 2 RCT patient par-
ticipant recruitment and data collection is active and on-
going. It is anticipated that patient participants’ postpar-
tum follow-up and thus data collection will be complete
in 2021. Data cleaning and primary planned analyses are
planned to be completed in 2022 (Additional file 1).
Phase 1: Run-in phase – feasibility of practice and patient
recruitment and data collection
Study phase 1 focused on practice recruitment and
characterization; this was designed to inform phase 2
randomization with covariate adaptive matching [50–52].
Critical to practices’ randomization was a demonstrated
ability to carry out study procedures including processes
that allowed patient participant recruitment by the study
team via phone, outside of the practice setting. To meet
criteria for randomization, each practice needed to have at
least 25 patient participants enrolled and at least one
patient participant who screened positive for depression.
Practice recruitment, including provider and staff
participants
Practices were recruited from July 2015 to February 2017
with the goal of geographic distribution across the state, di-
versity of practice environment (e.g. academic, private
practice), and socioeconomic and racial diversity among
the patients they serve. Within practices, participating pro-
viders and staff included attending and resident physicians,
advanced practice nurses, nurses, midwives, patient care
assistants, social workers, administrative support staff, and
others serving the practices’ patients.
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Practice-level measurements, assessments, data collection
procedures
Each practice completed a multi-component Practice
Readiness to Evaluate and address Perinatal Depression
scale (PREPD), to be described in a forthcoming manu-
script. This produced a cumulative baseline Practice
Readiness Index (PRI) score that indicated the extent to
which individual practices had integrated depression care,
and was used to inform randomization and provided a
benchmark against which to measure future change.
Provider participants completed a modified Smoking
Knowledge, Attitudes, and Practices Instrument (S-KAP)
[53], a 46 item tool that we adapted for use in obstetric
settings. To capture data not included in the measures,
we added questions with a five-level Likert Scale inquir-
ing about provider participant perspectives of the inter-
vention components’ usefulness, and their perceptions
of their own self-efficacy to manage depression, adequate
access to depression care, ability to ensure patients get
needed treatment in a timely manner, and ability to meet
the mental health needs of women.
Patient participant eligibility/ineligibility criteria and
recruitment time points
Patient participant enrollment eligibility for the run-in
phase was less stringent than in phase 2 (see Phase 2
below). For example, patients were eligible for recruitment
regardless of depressive symptomatology based on the Ed-
inburgh Postnatal Depression Scale (EPDS). Additionally,
patients were not excluded from recruitment based on a
positive 4Ps (Pregnancy, Past, Partner, Parents) substance
use disorder screen or Mood Disorder Questionnaire
(MDQ) bipolar disorder screen. To include patient partici-
pants with differential depressive symptom onset times,
patients were recruited during pregnancy and through
three months postpartum and had only a single point of
study contact. The broad inclusion criteria in the run-in
allowed us to examine the prevalence of depressive symp-
toms and other conditions and demographics within a
broader sample from the practices. This data was then
used to inform randomization and to phase 2 recruitment.
Phase 2: Randomized controlled trial
Study phase 2, which is ongoing, started with practice
randomization into the two intervention arms: [1]
MCPAP for Moms only, and [2] PRISM (see Intervention
descriptions below). Randomization was informed by
practice-level and patient-level data collected in phase 1.
Patient participant recruitment procedures are similar to
those in phase 1: they are recruited by study staff via
phone outside of the practice in a blinded fashion. How-
ever, in phase 2, patient participants are enrolled for longi-
tudinal data collection and serial assessments, and are to
be maintained in the study until 12months postpartum.
Randomization and allocation procedures
Although cluster randomization provides protection
against heterogeneity that may occur due to patient par-
ticipants in a practice not being independent, serious
imbalances can occur as practices often have vastly dif-
ferent patient profiles; thus, the baseline assumption that
the treatment groups are equal, subsequently hindering
any causal inferences, is threatened. To protect against
this threat, a restricted randomization technique using
minimization was employed allowing for balanced allo-
cation of practices to treatment arms on important pa-
tient characteristics. Data on practice readiness,
quantified as the Practice Readiness Index (PRI) score,
patient depressive symptom prevalence and severity as
per the EPDS, as well as socioeconomic status indicated
by insurance status, and non-white race/ethnicity, gath-
ered during study phase 1, were used to characterize
practices and formed the basis for restricted
randomization. Specifically, covariate adaptive matching
using Mahalanobis matching randomization was used
[50, 51]. Mahalanobis distances were used to determine
the optimal matches of practices, given the covariates
under consideration; then, practices were randomized
within the matched pairs. Five practices were random-
ized to each of the two interventions being evaluated.
Table 1 displays the results of the randomization
process. The randomization procedure matched prac-
tices on five factors deemed most relevant a priori; dis-
tributions of these factors are not statistically significally
different between the two intervention groups.
Interventions
Both interventions have been described elsewhere [35,
40, 42, 47], including a table of key characteristics [35],
and thus are briefly outlined here.
MCPAP for Moms alone [35, 40, 42] MCPAP for
Moms is a population-based, program available to all Ob/
Gyn practices throughout the state of Massachusetts.
MCPAP for Moms consists of training and toolkits, pro-
vider access to perinatal psychiatric consultation via tele-
phone and face-to-face as needed, and facilitation
of access to mental health resources and referrals cataloged
in a living inventory that is regularly updated. Statewide
provider access to MCPAP for Moms is essential to main-
tain ethical standards.
PRogram in support of Moms (PRISM) [35, 47]
PRISM includes MCPAP for Moms plus additional train-
ing, technical assistance, and implementation and change
management support, utilizing the ten step model of Ad-
dressing Problems Through Organizational Change [35,
54, 55]. PRISM is a multi-pronged intervention that has
core and optional elements. PRISM aims for practices to
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engage in systematic depression screening, assessment,
and stepped treatment response; additionally, it provides
proactive treatment engagement and patient monitoring
of all patients with depressive symptoms to ensure that
patients initiate, receive, and respond to treatment. PRISM
is customizable to each practice; in fact, it evolves over
time as practices iteratively identify steps to achieve their
self-identified goals. Core elements include: 1) an assess-
ment of practice readiness to implement PRISM (the
PREPD evaluation); 2) identification of practice-level
champion(s) and a work group to implement change plans
through practice-identified strategies and tactics; 3) pro-
vider and staff training and toolkit customization to facili-
tate stepped-care within the specific practice environment;
4) on-site implementation assistance by the investigative
team; and, 5) ongoing sustainment meetings and support
to sustain change. As part of the proactive patient moni-
toring, a non-physician navigator maintains a registry of
all patients with a positive depression screen. The naviga-
tor facilitates treatment engagement through motivational
interviewing and provision of psychoeducation, while
performing direct patient outreach, offering additional
referrals, and ensuring patient engagement (and re-
engagement as needed) in recommended medication
treatment and attendance at mental health appointments
via weekly to at least monthly follow-up calls. Patient
monitoring also includes ongoing observation of symp-
toms thus allowing providers to determine whether a
higher level of stepped-care is warranted at any stage in
the treatment process. Finally, a MCPAP for Moms peri-
natal psychiatrist reviews cases twice per month with the
navigator to provide expert consultation and education on
management and treatment engagement.
Practice-level assessments
Practices that successfully completed phase 1 were ran-
domized as indicated above. Their phase 1 data consti-
tutes a baseline, with subsequent data to be collected
yearly and at study completion. Table 2 details practice
participation data, adherence, fidelity, and acceptability
data to be collected longitudinally.
Patient participant recruitment procedures and eligibility/
ineligibility criteria
The study team worked with the practices to implement
protocols for systematically identifying patient partici-
pants. Lists of potential participants were compiled by
the offices and shared securely with the study team after
appropriate permissions were secured and safeguards
were in place. Some practices used an opt-in approach
where the office staff collected lists of patients agreeing
to be contacted by the study staff and forwarded that list
securely to the study staff. Other practices securely pro-
vided comprehensive lists of practice patients to study
staff and thus the study team was the first point of
contact.
Study flyers, fact sheets, HIPAA authorization forms,
and introductory letters signed by each respective prac-
tice director were mailed to patients asking them to opt
out if uninterested. Approximately two weeks after the
mailing, script-based telephone recruitment efforts
ensued. During phone recruitment, potential patient
participants verbally consented to study participation
and gave authorization for access to medical records.
Phone recruitment scripts included the EPDS, the 4Ps,
and the MDQ. The EPDS is a validated, 10-item screen-
ing questionnaire that is widely used to assess depression
during pregnancy and the postpartum period [44]. The
intensity of depressive symptoms is rated for the preced-
ing seven days, and each item is scored on a 4-point
scale for a total score range of 0–30, with higher scores
reflecting a greater severity of symptoms [44]. The 4Ps is
a validated screen [56] used to look for evidence of ac-
tive substance abuse and the MDQ [57] is used to screen
for bipolar disorder. Finally, other factors associated with
mental health treatment participation as well as
Table 1 Results of the factors used in matching during Randomization and presented by intervention arm
Factor Mean (SD) Difference P-value
MCPAP for Moms
(n = 5 practices)
PRISM
(n = 5 practices)
EPDS Score* 14.19 (0.91) 14.92 (2.31) −0.74 0.53
Prevalence Depression 23.1 (6.66) 20.01 (5.92) 3.08 0.61
Prevalence Public Insurance 48.76 (32.16) 57.95 (36.4) −9.18 0.68
Prevalence Non-White 36.38 (16.95) 42.51 (23.75) −6.14 0.69
Practice Readiness Index≠ 7.07 (1.99) 8.27 (0.82) −1.20 0.25
Table 1 represents the results of the reweighted Mahalanbois Distance/Covariate Adaptive matching procedure. Matching was done on the five factors deemed
most relevant a priori to matching procedures. Factors are reported as mean (standard deviation) by intervention arms in addition to differences and associated
p-values. Intervention arms were the PRogram In Support of Moms (PRISM) versus Massachusetts Child Psychiatry Access Program (MCPAP) for Moms
interventions. *Mean Edinburgh Postnatal Depression Scale (EPDS) score among those with an EPDS ≥10. ≠ The Practice Readiness Index (PRI) was a cumulative
score (total possible 16 points) derived from the multi-component Practice Readiness to Evaluate and address Perinatal Depression (PREPD) scale.
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education, insurance status, and race/ethnicity are col-
lected during phone recruitment.
Patient participants are considered eligible for phase 2
only if they demonstrate depressive symptomatology on
the EPDS, with a score ≥ 10. Patient participants are ineli-
gible for participation when there is evidence of active
substance abuse on the 4Ps, or a positive screen for bipo-
lar disorder via the MDQ. This is in contrast to phase 1,
where the EPDS, MDQ, and 4Ps measures were used only
to estimate rates of positives screens of depression, bipolar
disorder, and active substance use and give projections for
phase 2 recruitment, rather than ineligibility criteria.
Other eligibility criteria includes: [1] female sex; [2]
age 18–45 years; [3] gestational age of > 4 weeks through
3months postpartum; [4] receiving care from a partici-
pating practice, [5] able to communicate in written and
spoken English; and [6] cognitively able to give informed
verbal consent. If patients are not eligible during phone
screening due to an EPDS< 10 but are otherwise inter-
ested in and eligible for participation, they are entered
into a holding pool and re-contacted by phone at subse-
quent pregnancy and early postpartum time points. They
are recruited into the study cohort at the time point they
have onset of depressive symptoms (EPDS ≥10).
Patient participant-level assessments and study procedures
Patient participants recruited in phase 2, depending on
their recruitment and first interview time point (4–24
weeks gestation, 32–40 weeks gestation, or 1–3months
postpartum), will be followed two to four more times
until 13 months postpartum. As outlined in Table 3,
several assessments are to be collected longitudinally.
Patient participants consent to audiotaped interviews for
the telephonic data collection. Total assessment time
was pre-tested to assure calls did not exceed a time
burden of greater than 60min. Standardized or psycho-
metrically validated tools were chosen to screen for
other comorbid psychiatric illnesses, as opposed to a
diagnostic interview, to limit respondent burden and
maintain the practicality and feasibility that is imperative
for this real-world study. In addition to the EPDS,
MDQ, and 4Ps measured initially, post-traumatic stress
disorder is screened for with the well-validated PTSD
Screen-Civilian Version (PCL-C) [58], and generalized
anxiety with the 7-item Generalized Anxiety Disorder
Assessment (GAD-7) [59]. Mother infant bonding is
assessed with the 10 item shortened version of the Post-
partum Bonding Questionnaire (S-PBQ) [60]. Access to
care is measured using the Barriers to Access to Care
Evaluation scale (BACE), a 30-item tool that assesses
barriers to accessing mental health care and includes a
‘treatment stigma’ subscale [61]. Patient participants’ be-
liefs and supports are assessed using the 30-item version
of the Patient Attitudes towards and Ratings of Care for
Depression (PARC-D), which allows the interviewer to
explore the likelihood that a patient would use specific
therapies for depression. A short, 14-question version of
the Defense Style Questionnaire (DSQ-28) is used to
screen for immature defenses which correlate with per-
sistent depression. Finally, a structured interview is con-
ducted to assess utilization of depression treatment, and
barriers and facilitators to treatment participation. Other
relevant survey questions (e.g. demographics) are col-
lected at baseline, and obstetric and delivery outcomes
at first postpartum visit (Table 3). Additionally, the cost
and potential indicators of savings related to the MCPAP
for Moms and PRISM interventions will be captured via
measures and data sources as indicated in Table 4.
Patient participant treatment initiation and sustain-
ment will be operationalized as attendance at and
Table 2 Practice and Provider/Staff Participant-Level Measures
Outcome/ Endpoint Measure Administration Time Points*
Baseline Mid-point Final
Practice Profile Practice characteristics Self-administered √
Participation Training log Research Coordinator (RC) collects ongoing
Assessment of Practice Readiness to Evaluate
and address Perinatal Depression (PREPD)
RC collects and self-administered
components
√ √ √
Five-level Likert scale for obstetric providers/staff Self-administered online or paper √ √ √
Adherence And Fidelity Assessment of Practice Readiness to Evaluate
and address Perinatal Depression (PREPD)
RC collects and self-administered
components
√ √ √
Measures of fidelity Self-administered online Every 3 months for PRISM
practices following intervention
implementation
Knowledge, Attitudes,
Acceptability, And Practices
Five-level Likert scale for obstetric
providers/staff
Self-administered online or on paper √ √ √
Table 2 represents the measures and time points at which practice participation, adherence, fidelity, and acceptability data are to be collected according to the
PRogram In Support of Moms (PRISM) protocol. Baseline data was collected as part of the phase 1 run-in data. *Time points refer to stage of PRISM study, with
baseline being prior to the start of patient recruitment, mid-point being one year after intervention implementation and final being two years
after implementation.
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Table 3 Patient Participant-Level Measures
Outcome/ Endpoint Measure Administration Time Points*
0–24 wks
GA
32–40
wks GA
1–3
mos PP
5–7
mos PP
11–13
mos PP
Demographics ➢ Structured interview Research Coordinator
(RC) administered
√† √† √†
Depression Severity ➢ EPDS RC administered √ √ √ √ √
Comorbid Anxiety Disorders ➢ GAD-7
➢ PCL-C
RC administered √ √ √ √ √
Knowledge, Attitudes,
And Treatment Participation
➢ Structured interview assessing mental
health treatment initiation and sustainment
and barriers and facilitators to treatment
participation
Structured interview
with RC
√ √ √ √ √
Help-Seeking ➢ BACE
➢ PARC-D
RC administered √ √ √ √ √
Infant Bonding ➢ S-PBQ RC administered √ √ √
Immature Defenses ➢ DSQ-28 (14 Questions) RC administered √ √
Obstetric Outcomes ➢ Structured interview assessing obstetric
course, birth outcomes (e.g. birth weight,
preterm delivery) and infant outcomes
Structured interview
with RC
√ √ √
Table 3 represents the time points and frequency at which different patient participant measures are administered according to the PRogram In Support of Moms
(PRISM) protocol for the Randomized Controlled Trial (RCT) phase of this study. Measures listed above do not include pre-screen and screening measures done
before first time point, including baseline characteristics, MDQ (mood disorder questionnaire), and 4Ps (pregnancy, past, partner, parents) substance abuse screen.
Patient participants that are recruited from the holding pool at later gestational ages or postpartum may not complete all measure time points. *Time Points refer
to participant’s gestational age (GA) period or postpartum (PP) period in weeks (wks) or months (mos). † Demographic questions asked at the time of the initial
study phone call with recruitment windows corresponding with the first half of pregnancy, second half of pregnancy, and early postpartum.
Table 4 Cost of PRISM and Indicators of Potential Savings
Outcome/ Endpoint Measure Data Source Time frame
Cost of PRISM ➢ Startup costs
➢ Cost of implementation includes
implementation team meetings and
initial training (including the opportunity
costs incurred by training participants)
and other investments necessary for
implementation
➢ Participation in, number and length of
implementation meetings, trainings to
prepare for PRISM implementation
Ongoing
➢ Operational costs: PRISM general ➢ Participation in, number and length
of PRISM sustainment meetings; cost
of depression registry
Ongoing
➢ Operational costs: Providers, staff,
and navigator
➢ PRISM Navigator, provider, and staff
time sampling
Occurs every 6 months for two years
after intervention implementation
➢ Operational costs: providers and staff ➢ PRISM provider and staff time sampling Occurs every 6 months for two years
after intervention implementation
Cost of MCPAP
for Moms
➢ Operational costs: MCPAP for Moms
(already in place)
➢ MCPAP for Moms data Ongoing
Indicators of cost
Saving Potential
➢ Compare hospitalization rates (medical,
obstetric, and psychiatric) for perinatal
patients receiving care from PRISM versus
MCPAP for Moms
➢ Self-report during structured interviews
with patients
➢ Cost per hospitalization based on average
cost, obtained from Massachusetts Health
Policy Commission, a publicly available
de-identified database
Ongoing
➢ Birth outcomes: birth weight,
preterm delivery
➢ Infant outcomes: hospitalizations
(NICU, special care nursery)
➢ Self-report during structured interview
with patients
Ongoing
Table 4 represents the costs and indicators of potential savings measures for the PRogram In Support of Moms (PRISM) protocol versus the Massachusetts Child
Psychiatry Access Program (MCPAP) for Moms. Time frames for data collection are varied.
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number of mental health visit(s), receipt of prescription by
an obstetrician, and adherence to medication regimen.
Statistical analysis, power and sample size estimation for
phase 2 RCT
Aligned with the overall study aims, there are two main hy-
potheses for which data analyses of the phase 2 RCT are
planned. Hypothesis 1 (primary outcome) is that perinatal
patient participants with depressive symptomatology receiv-
ing care from practices enrolled in PRISM will experience
more improvement in depression symptoms than patients
receiving care from MCPAP for Moms only practices (2
point difference-of-difference in EPDS). To specifically com-
pare the difference in EPDS score over time between inter-
vention arms, the treatment by time interaction will be
evaluated. All analyses will be conducted using an intent-
to-treat framework. Hypothesis 2 (secondary outcome) is
that perinatal patient participants with depressive symp-
tomatology receiving care from practices enrolled in PRISM
will have improved treatment initiation and sustainment as
compared to patients receiving care from MCPAP for Moms
only practices. Patient participant treatment initiation and
sustainment can be represented as dichotomous variables.
Additionally this outcome can be assessed by counting the
number of mental health visits within a prescribed time-
frame. As in hypothesis 1 analyses, the treatment by time
interaction will be of primary interest and adjustment for
potential confounders (e.g., patient depressive symptom se-
verity, non-white race/ethnicity, insurance status, and PRI).
Power and sample size estimates were based on hy-
pothesis 1. Cluster randomized trials pose unique prob-
lems for sample size estimation and power. Within-
cluster similarities require samples sizes to be larger
than when using individual randomization [62]; thus an
inflation factor representing the correction to the vari-
ance was used to calculate an appropriate sample size.
Based on a prior study involving perinatal participants
with depressive symptoms, where the mean baseline EPDS
score was 14.8 (SD = 5.3) and the mean final EPDS score
was 9.7 (SD = 5.3) [37], we expect PRISM to cause a
decrease in EPDS score of 5 points. We also expect the
MCPAP for Moms only intervention to result in a decrease
of 3 points in the EPDS resulting in a net difference be-
tween the two treatment arms of two points at follow-up
[35]. Basing our sample size calculations on a two-sided,
two-group, t-test of means with equal N’s and alpha = 0.05,
we will have 80% power to detect this 2 point (small to
medium Cohen effect size) difference at follow-up (effect
size = 0.377) when the sample size is 112 patient partici-
pants per arm.
To account for clustering, we further increased these
estimates by an inflation factor given by the equation:
IF = [1 + (m – 1) ρ], where m represents the number of
patients per practice, and ρ represents the intraclass
correlation coefficient (ICC), the ratio of between-
cluster variation to total variability. We estimate the ICC
will be approximately 0.001 similar to values seen in
other studies [63]. Calculating the inflation factor and
adjusting previous power calculations, we seek to main-
tain 80% power to detect the desired difference, thus we
will need a sample size of 115 patient participants per
arm. Further, inflating our sample to account for 20%
noncompliance and dropout reveals that we will require
a final sample size of 150 patient participants per arm (5
practices per arm at 30 patient participants per practice).
Of the 10,500 pregnant patients that will be available to
be screened from participating practices, we conserva-
tively expect that 10% (n = 1,500) [2, 64] will screen
positive for depression on the EPDS (EPDS ≥10). Of
those, we expect that 25% (n = 375) will not meet eligi-
bility criteria for the study and that 50% (n = 750) will
consent to the study. Thus, we plan to recruit three pa-
tient participitants per week over a period of two years
to reach our sample size target of 300.
Based on our pilot work [35, 47] and our well-
established approaches for recruiting participants and
minimizing attrition/increasing retention, attrition rates of
less than 15% among Ob/Gyn clinics/practices and less
than 20% dropout of patient participants are expected.
The run-in phase was conducted to ensure that the study
procedures are feasible for the participating practices. The
Ob/Gyn practices are regularly engaged by phone, email,
and in person meetings. A retention rate of ≥80% of pa-
tient participants is anticipated because: [1] first contact is
close to the initial assessment; [2] detailed locator infor-
mation for the participant and two alternate contacts are
obtained; [3] multi-method engagement strategies are
used to proactively reach out to participants; [4] patient
participant calls are scheduled at flexible times including
evening availability; and, [5] patient participants are remu-
nerated $25 for each completed assessment and then $30
at the final completed assessment.
Regardless of whether a participant has a complete
record at each assessment, all available data will be used.
Completely at random, missing at random, or missing
not at random/non-ignorable [65, 66] data will be
assessed and will be addressed appropriately.
Quality assurance, subject protections and data requests
Standard operating procedures for quality assurance/
quality control (QA/QC) take place in the UMass Med-
ical School Quantitative Methods Core. Staff are trained
and provided clear guidance on data collection, quality
assurance, and standardized procedures for transmitting
data in accordance with protocols. Our data collection
software systems are programmed with validation rules.
Study staff administer assessments using electronic data
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capture with software systems that contain built-in
checks for validity, consistency, logic, appropriate skip
patterns and normal range values.
The PI, Co-PIs and Project Director provide oversight
and direction to the study staff to ensure study protocol
and procedures are followed and any issues are tracked and
corrected. The Project Director trains all study staff to con-
duct interviews using a standardized and neutral assess-
ment technique. The Project Director reviews a sampling
of recorded patient consents and assessments for the first
month that study staff conduct assessments independently.
A 10% random sample of the assessments are reviewed an-
nually to ensure that the data entered is consistent with
participants’ answers during audiotaped assessments and
for consistency of interview technique across study staff.
The Project Director then provides feedback to study staff
regarding interview approach and errors in data entry, and
develops a plan to avoid any further errors.
Any protocol deviations are reviewed by the PI who de-
termines if modifications to the study protocol or consent
form are required. A Data Safety Monitoring Board
(DSMB) was convened and acts in an expert, independent
advisory capacity. Protocol deviations are reported to the
DSMB as indicated. The DSMB includes three members
with expertise in perinatal psychiatry, Ob/Gyn, and meth-
odology. The DSMB responsibilities are to: [1] conduct in-
terim and final evaluations of the study, including analysis
of aggregate and individual participant data related to
safety, data integrity and the overall conduct of the study;
[2] consider factors external to the study when relevant
information becomes available, such as scientific or thera-
peutic developments that may have an impact on partici-
pant safety, scientific integrity, or the ethics of conducting
the study; [3] protect the safety of study participants; [4]
review and evaluate ad hoc safety issues concerning the
study at the request of the investigator(s); and, [5] make
recommendations to the investigator(s) concerning con-
tinuation, termination, or other modifications of the study
based on the observed benefits or adverse effects of the
study. The DSMB meets every six months. Additionally it
meets, 15months after the start of the RCT data collec-
tion, upon completion or termination of the study, within
48 h of an adverse event or protocol violation, and on an
ad hoc basis if there is deemed to be an imminent partici-
pant safety issue. At each meeting, the DSMB determines
whether the study should continue as planned, proceed with
modifications, or be terminated. Justification to terminate
may be due to the DSMB’s analysis that there is an over-
whelming safety issue or that recruitment is insufficient.
The complete DSMB charter is available upon request.
The study protocol is in compliance with the NIH Data
Sharing Policy and Implementation Guidance (http://grants.
nih.gov/grants/policy/data_sharing/data_sharing_guidance.
htm) and the NIH Statements on Sharing Research Data
and on Availability of Research Results: Publication, Intellec-
tual Property Rights, and Sharing Research Resources. Data
will be categorized to meet requirements for protected
health information, stripped of all study identification codes,
and will be transmitted in encrypted or otherwise secure
files for use according to the plans and policies of NIH,
CDC and participating investigators and institutions. In ac-
cordance with the PRISM Publication Guidelines and
Agreement (available upon request), data requests are sub-
mitted to the publication committee and minimally include
the primary question, proposed analyses/sample, and pur-
pose. The PRISM publication committee includes UMass
and CDC team members. Prior to receiving PRISM data, all
researchers are expected to sign a data use agreement.
Discussion
Recognizing maternal mental health as critical to quality
perinatal care and maternal safety, the Council on Patient
Safety in Women’s Health Care established a maternal
mental health safety bundle summarizing existing evi-
dence informed recommendations, paired with resources
[15, 67]. However, unlike prior bundles including those
addressing obstetric hemorrhage [68] and hypertensive
crisis [69], the maternal mental health bundle presents
unique implementation challenges as its scope spans
across multiple disciplines (e.g. obstetrics, psychiatry,
psychology and others) and is beyond the hospital mater-
nity unit, precluding it from being adequately addressed
with usual approaches like standardized order sets, drills,
and dedicated carts [68, 69]. Thus, interventions are
needed that address patient, provider, and system level
barriers to the successful integration of depression care
into outpatient obstetric practice [20–22].
Despite the clear need, there are a limited number of
interventions aimed at integrating obstetric and depres-
sion care [14, 34]. Existing interventions that demon-
strate feasibility, effectiveness, and acceptability [34] are
rigid in their structure, and, with limited exceptions
[35–39], have focused almost exclusively on process ra-
ther than outcome measures, or have either not ad-
dressed sustainability or do not exist beyond their grant
funding and research team support [34]. In response, in
this cluster-RCT, we are rigorously comparing the extent
to which PRISM improves depression symptomatology
and treatment participation among perinatal women as
compared to MCPAP for Moms while also estimating
costs and indicators of potential savings.
Our design allows us to evaluate two interventions,
MCPAP for Moms and PRISM, which target all obstetric
practices in the state and individual practices respectively.
Both MCPAP for Moms and PRISM recognize that ob-
stetric practices are complex evolving systems and thus
predetermined, one-size fits all approaches are limited in
their effectiveness. This cluster-RCT recognizes the
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practice as the natural unit of randomization. Moreover, it
innovates and advances the field by integrating obstetric
and psychiatric care by invoking implementation research
principles and participatory action research in a random-
ized controlled trial [70]. Important concepts of participa-
tory action research include that key intervention
elements are locally implemented based on collaborative
discussions, that on-site champions are collaborators and
share authority with study team, and that local insights in-
form implementation processes and general understand-
ing to improve addressed issues [70].
The participatory action research framework allows
practice-specific goals and processes to vary within
boundaries facilitated by a standardized menu of options,
that are offered to practices and customized to meet their
needs. This allows for the rigor of RCTs to be
generalizable in the context of organizations which all
have unique characteristics and conditions. Accordingly,
PRISM is a multi-pronged intervention with a structured
implementation process that empowers and supports
practices in identifying practice-specific goals and solu-
tions, through an iterative approach that maintains core
components across all practices, while allowing for
customization to specific practice environments. PRISM is
also unique in that it builds on MCPAP for Moms by add-
ing more intensive and proactive practice-specific goals
and activities. MCPAP for Moms is a statewide program
that leverages limited resources to improve access to men-
tal health resources across the state of Massachusetts in-
cluding ready access to perinatal psychiatrists [40, 42]. In
the first 5 years since the program went live, MCPAP for
Moms is seen as a national model and has influenced state
and national policies [41, 71–73]. MCPAP for Moms was
the inspiration behind the Bringing Postpartum Depression
out of the Shadows Act (H.R. 3235) [71, 74], which was
consolidated into twenty-first Century Cures and signed
into law. This legislation led to the appropriation of $5,000,
000 in the FY 18–19 federal budget for the United States
Health Resources and Services Administration (HRSA) to
administer grants for other states to establish perinatal
psychiatry access programs, similar to MCPAP for Moms
[75, 76]. Seven U.S. states (FL, KS, LA, MT, NC, RI, VT)
were recently awarded the grants each to establish their
own perinatal psychiatry access programs [77].
Compared to MCPAP for Moms, PRISM is more
focused on the individual practice level, and uses existing
infrastructure and resources within practice settings [35,
47]. Our study carries the potential for its results to have
policy and public health implications because both inter-
ventions have the potential to be feasible, sustainable, and
transportable to other practice settings. Given this poten-
tial, indicators of potential cost-savings will be collected in
phase 2 as successful dissemination of any program is reli-
ant not only on positive results but also on financial
sustainability and demonstration of short- and/or longer-
term investment return with consideration of program-
matic costs, and effect on maternal and child outcomes.
Another unique feature of our study design is that it
allows us to recruit women at three time points in order
to account for the different time periods for depressive
symptom onset. Our holding pool will also allow us to
follow a cohort of women and monitor for the onset of
depression and factors associated with symptom onset.
The run-in phase of this protocol demonstrated the
feasibility of practice and patient participant recruitment.
Our randomization approach protects against heterogen-
eity within practices as well as imbalances at the individual
level caused by practices having different patient profiles.
Effective investigations of programs that benefit peri-
natal women by addressing their mental health are greatly
needed. The public health impact of such interventions
has great potential given the intergenerational effects of
perinatal depression. Our MCPAP for Moms and PRISM
interventions target obstetric practices with the goal of in-
creasing their capacity to adequately address depression in
perinatal women. They each capitalize on and extend
beta-testing [47], pilot trials [35], and state-wide program
development [40, 42], all of which have identified contin-
ued gaps in the perinatal depression care pathway and
have informed iterative changes with the goal of continued
improvements for the benefits of mothers and their men-
tal health. Once the full trial is complete, we will dissemin-
ate findings via a multi-dimensional strategy that will
involve traditional academic and scientific venues, in
addition to advanced social media applications, and other
contemporary approaches.
Additional files
Additional file 1: The study timeline includes major study milestones
and corresponding dates. (PDF 130 kb)
Additional file 2: There are 10 practices that were randomized for this
study. The table includes the names of the practices, the region of
Massachusetts in which they are located, and their location (city or
town). (DOCX 13 kb)
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